NCT06982040View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Primary IgA Nephropathy
Interventions
DRUG

NTQ5082 capsules 100 mg

NTQ5082 capsules 100 mg

DRUG

NTQ5082 capsules 200 mg

NTQ5082 capsules 200 mg

DRUG

NTQ5082 capsules 300 mg

NTQ5082 capsules 300 mg

DRUG

Placebo

Placebo

Sponsors
All Listed Sponsors
lead

Nanjing Chia-tai Tianqing Pharmaceutical

INDUSTRY